Format

Send to

Choose Destination
Leukemia. 2017 Apr;31(4):997-1000. doi: 10.1038/leu.2017.5. Epub 2017 Jan 11.

Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study.

Author information

1
Wilhelminen Cancer Research Institute, Wilhelminenspital Wien, Wien, Austria.
2
Internal Medicine II, University of Tübingen, Tübingen, Germany.
3
Department of Hematology, 'Sapienza' University of Rome, Rome, Italy.
4
Hématologie et Thérapie Cellulaire, Hôpital de La Milétrie, CHU, Inserm CIC 1402, Poitiers, France.
5
Department of Oncology and Hematology, Niguarda Ca'Granda Hospital, Milano, Italy.
6
Department of Hematology, CHU St Antoine, Paris, France.
7
IIIrd Medical Department, Paracelsus Medical University Salzburg, Salzburg, Austria.
8
Hématologie, CHU de Lille, Inserm U995, Université Lille 2, Lille, France.
9
NOXXON Pharma AG, Berlin, Germany.
10
Internal Medicine I, University of Freiburg, Freiburg, Germany.
PMID:
28074071
PMCID:
PMC5383929
DOI:
10.1038/leu.2017.5
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center